文献速递疼痛医学

将大麻产品审慎整合进慢性疼痛治疗

Thoughtfully Integrating Cannabis Products Into Chronic Pain Treatment.
PubMed 文献 · Anesth Analg · 2023-12-15

本文是一篇叙述性综述,针对大麻产品(CPs)和大麻基药物(CBMs)用于疼痛管理证据有限但使用普遍的现状,提出临床医生应以治疗联盟、危害减少与获益最大化、务实与以患者为中心的临床判断三原则与患者沟通。

要点

  • 现有临床试验产品与剂量方案无法推广至当前市场,证据不足以支持或否定CBMs用于疼痛管理。
  • 观察性 literature 显示许多人用CPs管理疼痛并替代其他药物。
  • 临床医生应遵循治疗联盟、危害减少与获益最大化、务实与以患者为中心三原则。

核心结论

  • 尽管CPs用于慢性疼痛管理的确定性不足,遵循三原则可把握讨论CPs带来的临床机会并提高临床获益可能性。

研究设计与样本

  • 叙述性综述,综合现有证据以清晰呈现当前格局并为临床医生提供务实建议。

主要发现

  • 临床试验文献有限,未否定也未支持CBMs用于疼痛管理。
  • 大量且增长的观察性文献显示许多人使用CPs管理疼痛并替代其他药物。
  • 现有试验中的产品与剂量方案无法推广至当前大麻市场,难以比较和调和两类文献。

关键数值与推荐

  • 三原则:维持治疗联盟;危害减少与获益最大化;务实、以患者为中心照护原则及在不确定中使用最佳临床判断。

临床怎么用

  • 临床医生可依据三原则对使用CBMs管理疼痛的患者进行教育与合作。

局限性

  • 临床试验证据有限且产品与剂量方案不可推广至当前市场。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cannabis products (CPs) and cannabis-based medicines (CBMs) are becoming increasingly available and are commonly used for pain management. The growing societal acceptance of cannabis and liberalization of cannabis laws allows patients to access CPs with minimal clinical oversight. While there is mechanistic plausibility that CPs and CBMs may be useful for pain management, the clinical trial literature is limited and does not refute or support the use of CBMs for pain management. Complicating matters, a large and growing body of observational literature shows that many people use CPs for pain management and in place of other medications. However, products and dosing regimens in existing trials are not generalizable to the current cannabis market, making it difficult to compare and reconcile these 2 bodies of literature. Given this complexity, clinicians need clear, pragmatic guidance on how to appropriately educate and work with patients who are using CBMs for pain management. In this review, we narratively synthesize the evidence to enable a clear view of current landscape and provide pragmatic advice for clinicians to use when working with patients. This advice revolves around 3 principles: (1) maintaining the therapeutic alliance; (2) harm reduction and benefit maximization; and (3) pragmatism, principles of patient-centered care, and use of best clinical judgment in the face of uncertainty. Despite the lack of certainty CPs and chronic pain management use, we believe that following these principles can make most of the clinical opportunity presented by discussions around CPs and also enhance the likelihood of clinical benefit from CPs.

来源:Anesth Analg,查看原文。版权归原作者所有。

引用

  1. Boehnke KF, Wu CL, Clauw DJ, et al. Thoughtfully Integrating Cannabis Products Into Chronic Pain Treatment. Anesth Analg. 2023. PMID: 38100797. doi:10.1213/ANE.0000000000005904

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。